HadrienDe Blander KU Leuven- VIBBelgium

Pharmacist by training, I am a postdoctoral researcher in the lab of Prof. Jean-Christophe Marine, where I investigate melanoma cell plasticity and therapy resistance. My work explores how cell scaling properties shape cell states and how we can leverage cell plasticity to design new therapeutic strategies.

Monday 08 June 2026

Time	Session

14:00 15:15	Top Abstracts Arkaitz Carracedo Perez Chair CIC bioGUNESpain Integration of stress response biology multi-omic datasets decodes prostate cancer dynamic disease progression and places IRE1 activity at the epicentre of acquired treatment resistance EACR26-1391 EACR26-1391 DimitriosDoultsinos Oral Presenter University of OxfordUnited Kingdom Temporal progression of the liver immune microenvironment during breast cancer metastasis EACR26-1906 EACR26-1906 CatarinaBarbosa-Matos Oral Presenter Champalimaud Centre for the Unknown Portugal Simple cell geometry metrics reveal cancer cell diversity and plasticity and guide combination therapy EACR26-0589 EACR26-0589 HadrienDe Blander Oral Presenter KU Leuven- VIBBelgium Protective PROTACs exploit cancer-specific E3 ligase defects to increase the therapeutic window of anticancer drugs EACR26-2000 EACR26-2000 LuciaSimon-Carrasco Oral Presenter CABIMER Spain Room P1+2+3

Time

Session

14:00

15:15

Top Abstracts

Arkaitz Carracedo Perez Chair CIC bioGUNESpain

Integration of stress response biology multi-omic datasets decodes prostate cancer dynamic disease progression and places IRE1 activity at the epicentre of acquired treatment resistance

EACR26-1391

EACR26-1391

DimitriosDoultsinos Oral Presenter University of OxfordUnited Kingdom
Temporal progression of the liver immune microenvironment during breast cancer metastasis

EACR26-1906

EACR26-1906

CatarinaBarbosa-Matos Oral Presenter Champalimaud Centre for the Unknown Portugal
Simple cell geometry metrics reveal cancer cell diversity and plasticity and guide combination therapy

EACR26-0589

EACR26-0589

HadrienDe Blander Oral Presenter KU Leuven- VIBBelgium
Protective PROTACs exploit cancer-specific E3 ligase defects to increase the therapeutic window of anticancer drugs

EACR26-2000

EACR26-2000

LuciaSimon-Carrasco Oral Presenter CABIMER Spain

Room P1+2+3